Advertisement

Regulatory and Evidence Requirements and the Changing Landscape in Regulation for Marketing Authorisation

  • Francesco PignattiEmail author
  • Elias Péan
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 213)

Abstract

In this chapter, we describe the changing landscape of the EU pharmaceutical legislation concerning regulation and evidence requirements for marketing authorisation. First, we describe the legal requirements for marketing authorisation and the development of EU pharmaceutical legislation and the concept of risk-benefit balance. Second, we describe special types of authorisation, such as conditional approval and approval under exceptional circumstances, and special provisions such as incentives for orphan medicinal products and paediatric investigational plans. Lastly, we describe the available methodological guidelines focussing on choice of endpoints.

Keywords

EMA Marketing authorisation Anticancer drugs Efficacy Benefit-risk balance 

References

  1. Commission Regulation (EC) No 2049/2005 of 15 December 2005 laying down, pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council, rules regarding the payment of fees to, and the receipt of administrative assistance from, the European Medicines Agency by micro, small and medium-sized enterprisesGoogle Scholar
  2. Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 92, 30 Mar 2006, pp 6–9)Google Scholar
  3. Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts: similar medicinal product” and “clinical superiority” (OJ L 103, 28 Apr 2000, pp 5–8)Google Scholar
  4. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (consolidated version: 16 Nov 2012)Google Scholar
  5. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (OJ L 136, 30 Apr 2004, pp 34–57)Google Scholar
  6. Eichler HG, Pignatti F, Flamion B et al (2008) Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 7(10):818–826CrossRefGoogle Scholar
  7. European Commission. EudraLex—volume 1—pharmaceutical legislation for medicinal products for human use. Secondary EudraLex—volume 1—pharmaceutical legislation for medicinal products for human use. https://ec.europa.eu/health/documents/eudralex/vol-1_en
  8. European Commission. 50 years of EU pharmaceutical legislation. secondary 50 years of EU pharmaceutical legislation. https://ec.europa.eu/health/human-use/50years_en
  9. European Medicines Agency (2012a) Guideline on the evaluation of anticancer medicinal products in man. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf
  10. European Medicines Agency (2012b) Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man—methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137126.pdf
  11. European Medicines Agency (2016a) 10-year report to the European Commission: general report on the experience acquired as a result of the application of the Paediatric Regulation (EMA/231225/2015). https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf
  12. European Medicines Agency (2016b) Final report on the adaptive pathways pilot (EMA/276376/2016). http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf
  13. European Medicines Agency (2016c) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC500205159.pdf
  14. European Medicines Agency (2016d) Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man—condition specific guidance (EMA/CHMP/703715/2012 Rev. 2). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500201945.pdf
  15. European Medicines Agency (2017) Conditional marketing authorisation: report on ten years of experience at the European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/01/WC500219991.pdf
  16. Hammond JS, Keeney RL, Raiffa H (1999) Smart choices: a practical guide to making better decisions. BostonGoogle Scholar
  17. Levitan B, Hauber AB, Damiano MG et al (2017) The ball is in your court: agenda for research to advance the science of patient preferences in the regulatory review of medical devices in the United States. Patient 2017Google Scholar
  18. Martinalbo J, Bowen D, Camarero J et al (2016) Early market access of cancer drugs in the EU. Ann Oncol 27(1):96–105CrossRefGoogle Scholar
  19. Pignatti F, Aronsson B, Gate N, et al (2002) The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. Eur J Clin Pharmacol 58(9):573–80CrossRefGoogle Scholar
  20. Pignatti F, Gravanis I, Herold R et al (2011) The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation. Clin Cancer Res 17(16):5220–5225CrossRefGoogle Scholar
  21. Pignatti F, Ashby D, Brass EP et al (2015) Structured frameworks to increase the transparency of the assessment of benefits and risks of medicines: current status and possible future directions. Clin Pharmacol Ther 98(5):522–533CrossRefGoogle Scholar
  22. Postmus D, Mavris M, Hillege HL et al (2016) Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther 99(5):548–554CrossRefGoogle Scholar
  23. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (consolidated version: 26/01/2007)Google Scholar
  24. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (consolidated version: 07 Aug 2009)Google Scholar
  25. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (consolidated version: 05 June 2013)Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.European Medicines AgencyLondonUK

Personalised recommendations